Thyroid cancer is the most common endocrine malignancy with an estimated 43,800 new
cases to be diagnosed in 2022 and representing the 7th most common cancer in women …

Molecular diagnostic testing has had a profound impact on the diagnosis and management
of thyroid nodules and thyroid cancer. Based on the tremendous expansion of knowledge of …

Objective Advances in our understanding of the molecular biology of thyroid tumours is
being rapidly translated into their clinical management. This review summarizes the current …

Thyroid nodules affect nearly two‐thirds of the world population. Fine‐needle biopsy with
cytologic evaluation remains the diagnostic test of choice to distinguish benign from …

Despite advances in imaging and biopsy techniques, the management of thyroid nodules
often remains a diagnostic and clinical challenge. In particular, patients with cytologically …

The historical management of thyroid nodules with indeterminate cytology has often been
with diagnostic lobectomy or thyroidectomy. There is a substantial downside to this …

Cytologically indeterminate thyroid nodules remain a diagnostic and clinical challenge, and
molecular testing has been advocated and advanced as a diagnostic modality to help guide …

Approximately 25% of the fine needle aspiration samples (FNAB) of thyroid nodules are
classified as “indeterminate samples”, that means, Bethesda III and IV categories. Until the …

Objective To describe the molecular markers thus far evaluated for use in the care of
patients with clinically relevant thyroid nodules. Methods We review the currently available …

Thyroid cancer is the most common type of endocrine malignancy, with approximately
55,000 new cases diagnosed in the United States in 2012. However, thyroid nodules are …